Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AVROBIO nets $130mm via FOPO

Executive Summary

Gene therapy firm AVROBIO Inc. netted $130mm via a follow-on offering of 7.48mm common shares (including full exercise of the overallotment) at $18.50 each. The company will use some of the proceeds for ongoing development of its candidates for Fabry disease, Gaucher disease, Pompe disease, and cystinosis.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies